IP Library › Granted Patent US 9,969,983
Granted Patent B2
US 9,969,983 · App. 15/844,063 · Granted May 15, 2018

Methods and products for transfection

Inventors: Matthew Angel (Cambridge, MA); Christopher Rohde (Cambridge, MA)
Assignee: FACTOR BIOSCIENCE INC.
C12N5/0696C12N5/0625C12N5/0647C12N5/0656C12N5/0657C12N5/0676C12N5/0695C12N5/0018C12N2500/25C12N2500/33C12N2500/36C12N2500/84C12N2501/602C12N2501/603C12N2501/604C12N2501/606C12N2501/608C12N2501/998C12N2506/09C12N2506/45
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,969,983
App. No.
15/844,063
Granted
May 15, 2018
Kind
B2
Abstract

The present invention relates in part to methods for producing tissue-specific cells from patient samples, and to tissue-specific cells produced using these methods. Methods for reprogramming cells using RNA are disclosed. Therapeutics comprising cells produced using these methods are also disclosed.

Claims (12)

1. A method for reprogramming a non-pluripotent cell comprising:

(a) providing a non-pluripotent cell, the non-pluripotent cell being derived from a biopsy of a human subject;

(b) culturing the non-pluripotent cell; and

(c) transfecting the non-pluripotent cell with a synthetic RNA molecule, wherein:

the synthetic RNA molecule encodes one or more reprogramming factor(s) selected from the group consisting of Oct4 protein, Sox2 protein, Klf4 protein, c-Myc protein, I-Myc protein, Tert protein, Nanog protein, and Lin28 protein,

the transfecting results in the non-pluripotent cell expressing the one or more reprogramming factor(s) which reprograms the non-pluripotent cell; and

step (c) is performed without using irradiated human neonatal fibroblast feeder cells and occurs in the presence of a medium containing ingredients that support reprogramming of the non-pluripotent cell.

2. The method of claim 1 , wherein the non-pluripotent cell is from a dermal punch biopsy sample.

3. The method of claim 1 , wherein the non-pluripotent cell is a skin cell.

4. The method of claim 1 , further comprising contacting the cell with at least one member of the group: poly-L-lysine, poly-L-ornithine, RGD peptide, fibronectin, vitronectin, collagen, and laminin.

5. The method of claim 1 , wherein the synthetic RNA molecule contains at least one of a pseudouridine or a 5-methylcytidine residue.

6. The method of claim 1 , wherein the medium is substantially free of immunosuppressants.

Assignments (2)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jan 8, 2018
From: ANGEL, MATTHEW; ROHDE, CHRISTOPHER
To: FACTOR BIOSCIENCE INC.
Reel/Frame 044565/0233 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Dec 20, 2017
From: ANGEL, MATTHEW; ROHDE, CHRISTOPHER
To: FACTOR BIOSCIENCE INC.
Reel/Frame 044921/0490 →
Continuity (10)
Continuation 15605513 · May 25, 2017
Continuation 15358818 · Nov 22, 2016
Continuation 15178190 · Jun 9, 2016
Continuation 14810123 · Jul 27, 2015
Continuation 13931251 · Jun 28, 2013
Continuation 13465490 · May 7, 2012
Provisional Application 61637570 · Apr 24, 2012
Provisional Application 61569595 · Dec 12, 2011
Provisional Application 61566948 · Dec 5, 2011
Related Publication 20180105800A1 · Apr 19, 2018